Header Logo

Connection

Michael Gould to Treatment Outcome

This is a "connection" page, showing publications Michael Gould has written about Treatment Outcome.
Connection Strength

0.862
  1. Early identification of COVID-19 cytokine storm and treatment with anakinra or tocilizumab. Int J Infect Dis. 2020 Oct; 99:291-297.
    View in: PubMed
    Score: 0.142
  2. Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study. J Thorac Oncol. 2011 May; 6(5):875-83.
    View in: PubMed
    Score: 0.075
  3. Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol. 2009 Dec; 4(12):1473-9.
    View in: PubMed
    Score: 0.068
  4. Timeliness of care in patients with lung cancer: a systematic review. Thorax. 2009 Sep; 64(9):749-56.
    View in: PubMed
    Score: 0.067
  5. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med. 2007 Jan 08; 167(1):74-80.
    View in: PubMed
    Score: 0.055
  6. A clinical prediction rule to estimate the probability of mediastinal metastasis in patients with non-small cell lung cancer. J Thorac Oncol. 2006 Nov; 1(9):953-9.
    View in: PubMed
    Score: 0.055
  7. When in doubt should we cut it out? The role of surgery in non-small cell lung cancer. Thorax. 2006 Jul; 61(7):554-6.
    View in: PubMed
    Score: 0.053
  8. Poor choice of primary outcome in a clinical trial of pirfenidone in patients with IPF. Am J Respir Crit Care Med. 2005 Nov 01; 172(9):1228-9; author reply 1229.
    View in: PubMed
    Score: 0.051
  9. Outcomes in critically ill patients before and after the implementation of an evidence-based nutritional management protocol. Chest. 2004 Apr; 125(4):1446-57.
    View in: PubMed
    Score: 0.046
  10. Variability in antibiotic prescribing patterns and outcomes in patients with clinically suspected ventilator-associated pneumonia. Chest. 2003 Mar; 123(3):835-44.
    View in: PubMed
    Score: 0.042
  11. Effect of Physical Activity Coaching on Acute Care and Survival Among Patients With Chronic Obstructive Pulmonary Disease: A Pragmatic Randomized Clinical Trial. JAMA Netw Open. 2019 08 02; 2(8):e199657.
    View in: PubMed
    Score: 0.033
  12. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials. Ann Intern Med. 1999 May 18; 130(10):800-9.
    View in: PubMed
    Score: 0.033
  13. Poor Outcomes After Emergency Department Discharge of the Elderly: A Case-Control Study. Ann Emerg Med. 2016 07; 68(1):43-51.e2.
    View in: PubMed
    Score: 0.026
  14. Patient-centered physical activity coaching in COPD (Walk On!): A study protocol for a pragmatic randomized controlled trial. Contemp Clin Trials. 2016 Jan; 46:18-29.
    View in: PubMed
    Score: 0.025
  15. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial. Trials. 2014 Dec 20; 15:502.
    View in: PubMed
    Score: 0.024
  16. Catheter-directed therapy for the treatment of massive pulmonary embolism: systematic review and meta-analysis of modern techniques. J Vasc Interv Radiol. 2009 Nov; 20(11):1431-40.
    View in: PubMed
    Score: 0.017
  17. Tuberculosis in liver transplant recipients: a systematic review and meta-analysis of individual patient data. Liver Transpl. 2009 Aug; 15(8):894-906.
    View in: PubMed
    Score: 0.017
  18. Asthma control, severity, and quality of life: quantifying the effect of uncontrolled disease. J Allergy Clin Immunol. 2007 Aug; 120(2):396-402.
    View in: PubMed
    Score: 0.014
  19. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol. 2006 Dec; 63(12):1686-91.
    View in: PubMed
    Score: 0.014
  20. Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity. Blood. 1995 Nov 01; 86(9):3287-94.
    View in: PubMed
    Score: 0.006

© 2024 Kaiser Permanente